Related Experiment Video
Updated: Aug 31, 2025
Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
Published on: August 14, 2012
DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms
James Yao1, Emily Bergsland2, Rahul Aggarwal2
1Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Introduction:
Neuroendocrine neoplasms (NEN) are heterogeneous malignancies that can arise at almost any anatomical site and are classified as biologically distinct well-differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC). Current systemic therapies for advanced disease, including targeted therapies, chemotherapy, and immunotherapy, are associated with limited duration of response. New therapeutic targets are needed. One promising target is delta-like ligand 3 (DLL3), an inhibitory ligand of the Notch receptor whose overexpression on the surface of NEN is associated with tumorigenesis.
Methods:
This article is a narrative review that highlights the role of DLL3 in NEN progression and prognosis, the potential for therapeutic targeting of DLL3, and ongoing studies of DLL3-targeting therapies. Classification, incidence, pathogenesis, and current management of NEN are reviewed to provide biological context and illustrate the unmet clinical needs.
Discussion:
DLL3 is overexpressed in many NENs, implicated in tumor progression, and is typically associated with poor clinical outcomes, particularly in patients with NEC. Targeted therapies using DLL3 as a homing beacon for cytotoxic activity mediated via several different mechanisms (eg, antibody-drug conjugates, T-cell engager molecules, CAR-Ts) have shown promising clinical activity in small-cell lung cancer (SCLC). DLL3 may be a clinically actionable target across NEN.
Conclusions:
Current treatment options for NEN do not provide sustained responses. DLL3 is expressed on the cell surface of many NEN types and is associated with poor clinical outcomes. Initial clinical studies targeting DLL3 therapeutically in SCLC have been promising, and additional studies are expanding this approach to the broader group of NEN.
Insights
Delta-like ligand 3 (DLL3) is a promising target for neuroendocrine neoplasms (NEN) as it is overexpressed in these tumors and linked to poor outcomes. Therapies targeting DLL3 show potential for treating advanced NEN, expanding beyond small-cell lung cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Neuroendocrine neoplasms (NEN) are diverse cancers with limited treatment response duration.
- Delta-like ligand 3 (DLL3) is overexpressed in NEN and associated with tumorigenesis and poor prognosis.
- Current therapies for advanced NEN offer limited long-term efficacy, highlighting the need for novel therapeutic targets.
Approach:
- This review synthesizes current knowledge on DLL3's role in NEN progression and therapeutic targeting.
- It covers NEN classification, incidence, pathogenesis, and current management strategies.
- The review examines ongoing clinical studies of DLL3-targeting therapies.
Key Points:
- DLL3 overexpression in NEN correlates with tumor progression and adverse clinical outcomes, especially in neuroendocrine carcinomas (NEC).
- DLL3 serves as a target for novel therapies including antibody-drug conjugates, T-cell engagers, and CAR-Ts.
- Therapeutic strategies targeting DLL3 have demonstrated promising clinical activity in small-cell lung cancer (SCLC).
Conclusions:
- DLL3 represents a clinically actionable target across various NEN types.
- Targeting DLL3 offers a promising therapeutic avenue for patients with advanced NEN.
- Ongoing research is expanding DLL3-targeted therapies from SCLC to other NEN.
